SARS CoV 2 Spike Antibody, IgG

The Abbott Architect SARS-CoV-2 IgG II assay, run under an emergency use authorization from the FDA, is quantitative test designed to detect IgG antibodies to the spike protein of SARS-CoV-2 in serum and plasma from individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are reported as AU/mL.

Reactive (Positive, ≥50.0 AU/mL) results may be due to immunization or past or present infection with SARS-CoV-2. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

Nonreactive (Negative, <50.0 AU/mL) results do not rule out SARS-CoV-2 infection, particularly in those who have recently been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals. Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.

For Batteries containing NCVIGQ refer to:

SARS-CoV-2 Antibodies (NCVIGG, NCVIGQ)[NCVIGB], The qualitative detection of anti-Nucleocapsid IgG (NCVIGG) and the quantitative detection of anti-Spike IgG (NCVIGQ) antibodies.

For all questions, contact Client Support Services (available 24/7):

Phone: (206) 520-4600 or (800) 713-5198
Fax: (206) 520-4903
Email: commserv@uw.edu

The test order requisition is available online